The Healthcare Cost and Utilization Project NIS has become the largest publicly available all-payer inpatient care database in the United States, which was developed by the (Federal) Agency for Health Care Research and Quality. 12 The NIS approximates a 20% stratified sample of all hospital discharge abstracts that consisted all nonfederal acute care hospitals, including community hospitals, public hospitals, academic medical centers, and specialty hospitals but excluded long-term care facilities. The approach with stratified random sampling ensures that the database content is representative of the U.S. population and that can be weighed to produce national estimates. Each discharge is treated as a unique entry and includes 1 primary diagnosis and up to 24 secondary diagnoses that are coded based on the International Classification of Diseases, the 9th Version, Clinical Modification (ICD-9-CM).
This study was approved for Institutional Review Board exemption at the Cleveland Clinic Foundation. The ICD-9-CM codes for the primary or secondary discharge diagnoses (see Appendix A for the list of ICD-9-CM codes, Supplemental Digital Content 1, http://links.lww.com/IBD/B463) were used to identify hospital discharges of patients with diagnosis of UC or Crohn's disease (CD) or familial adenomatous polyposis (FAP) that had a concomitant discharge diagnosis of pouchitis (ICD-9-CM code 569.71). Patients with CDI were identified by discharge diagnosis code 008.45 and were categorized as having C. difficile pouchitis. The definition of C. difficile pouchitis was based on the presence of diagnostic codes of "pouchitis" and CDI. The ICD-9-CM codes for C. difficile were validated in previous studies. 13, 14 The subgroup of patients with "FAP" was studied only to assess the rates of C. difficile pouchitis. To examine the risk factors associated with C. difficile pouchitis and its impact on hospital-based outcomes, we selected the "UC" and "CD" groups for final analysis. Figure 1 provides the algorithm for inclusion of the study population.
Inclusion and Exclusion Criteria
We identified all discharges for adults aged #18 years with a primary or secondary discharge diagnosis of UC, CD, and FAP with a concomitant diagnosis of pouchitis using the ICD-9-CM codes ( Fig. 1) . Patients who carried clinical diagnosis of both UC and CD were categorized as "unclassified inflammatory bowel disease (IBD)" and were excluded from the study population.
Definitions of Variables
Appendix A (see Supplemental Digital Content 1, http:// links.lww.com/IBD/B463) lists the ICD-9-CM diagnoses used in this study. Pouchitis patients were classified based on underlying diagnosis as IBD-related pouchitis (i.e., the presence of either UC or CD) or as FAP-related pouchitis. Covariates included patient age, categorized as 18 to 64 years and $65 years; gender; health insurance status, classified as private insurance, Medicare, Medicaid, or other/uninsured; race and ethnicity, categorized as white, African American, Hispanic, and others. The ethnicity was the factor with most missing data (8%) as certain States do not document race in the discharge information; we included this as a separate category under 'unknown' said variable. We studied the Elixhauser comorbidity algorithm, which is a commonly used risk adjustment measure derived from the hospital discharge abstract. Thirty chronic comorbidities were further categorized as "0," "1," "2," and "$3"; the presence of certain diseases that are associated with pouchitis were also obtained using ICD-9-CM diagnosis codes for primary and secondary diagnoses. This included concurrent immune-mediated disorders, such as primary sclerosing cholangitis, celiac disease, rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenia, multiple sclerosis, Hashimato's thyroiditis, and asthma; and infections such as cytomegalovirus, and the presence of intestinal ischemia. Metabolic diseases including nonalcoholic fatty liver disease (NAFLD) and obesity, obstructive sleep apnea (OSA), and metabolic syndrome, were identified using appropriate ICD-9-CM codes. The diagnosis code for "other chronic nonalcoholic liver disease" was used to identify NAFLD. Metabolic syndrome was defined as presence of at least 3 of 4 following chronic conditions: hypertension, dyslipidemia, diabetes mellitus, and obesity. 15 Obesity, hypertension, and diabetes mellitus were documented by the presence of comorbid conditions, and dyslipidemia was identified using appropriate ICD-9-CM codes. The variable "Pouch failure" was defined by the presence of concomitant ileostomy procedural codes (see Appendix A, Supplemental Digital Content 1, http:// links.lww.com/IBD/B463), assuming that patients underwent fecal diversion surgery during the hospitalization.
Outcome Measurement
Our primary outcome was the frequency and risk factors associated with C. difficile pouchitis. The secondary outcomes were the hospital LOS and hospitalization costs associated with CDI pouchitis.
The primary outcome was the discharge (the primary or secondary) diagnosis of CDI identified with an ICD-9-CM diagnosis code (008.45). The secondary outcomes of interests were all-cause in-hospital mortality and were provided in the data set as "died" during the hospitalization encounter; pouch failure rate, provided by the presence of procedural codes for "ileostomy"; hospital LOS defined as the total number of days from admission to discharge; hospital costs were adjusted for inflation to 2012 U.S. dollars using the gross domestic product deflator (Price Indexes for Gross Domestic Product, the U.S. Department of Commerce, Bureau of Economic Analysis). 16 Patients with missing outcome variable were not considered in the final multivariable analysis.
Statistical Analysis
Data are shown as mean 6 SD for continuous variables or weighted frequency (%) for categorical factors. A univariable analysis was performed to assess differences between the baseline characteristics of subjects with UC and those with CD; continuous variables were compared using t tests and categorical variables were compared using Rao-Scott chi-square tests. The frequency analyses were performed for each subgroup of pouchitis, i.e., IBD-associated pouchitis and FAP-associated pouchitis. The frequency of CDI was expressed as CDI cases per 100 hospitalizations. For risk factors assessment for CDI and for secondary outcomes analysis, only patients from IBD-associated pouchitis were included. FAP-related pouchitis had relatively small number of patients and had no single event of CDI and was not included in the risk assessment analysis. Multivariable analysis was also performed to evaluate factors associated with CDI; gender and IBD diagnosis (UC or CD) were forced in this model with CDI as outcome variable; a backward elimination selection method was used to choose other factors to include in the final model and factors with P , 0.10 were also kept in the model. In addition, univariable and multivariable linear regression analyses were performed to assess factors associated with LOS and total charges; CDI was included in all models and backward elimination selection method was used to choose the final models, and CDI and other factors with P , 0.10 were kept in the models. The above analyses were conducted using SAS Survey Procedures (version 9.4; SAS Institute Inc., Cary, NC), and a P , 0.05 was considered statistically significant.
RESULTS
A total of 3470 eligible patients with pouchitis were identified in the IBD group and 96 patients with pouchitis in the FAP group.
Frequency of C. difficile Pouchitis in IBD and FAP
CDI was identified in 2.6% (99.9% confidence interval [CI], 1.3-3.8) of pouchitis patients with underling IBD. Among these patients with C. difficile pouchitis, 66.2% had CDI as the primary discharge diagnosis. The frequency of C. difficile pouchitis was not statistically different between those with UC and those with CD (2.5% versus 2.8%; P ¼ 0.79). However, CDI as a primary discharge diagnosis was more common in the CD group than the UC group (2.8% versus 1.08%; P ¼ 0.04). Table 1 presents the frequency rates of CDI among pouchitis patients with underlying IBD and FAP. None of the pouchitis patients in the FAP group had a concomitant diagnosis of CDI. Table 2 presents the demographic and disease characteristics for 3470 patients who carried a diagnosis of pouchitis with a concomitant diagnosis of UC and CD; 36.4% of these patients had pouchitis as their primary diagnosis. Of these 3470 patients, 2203 (63.5%) had UC and 1267 (36.5%) had CD. The majority of the patients were younger than 65 years. There was no gender difference in the rates of pouchitis (P ¼ 0.74). We observed differences in the proportion of patients admitted with "pouchitis" as the primary diagnosis; pouchitis was the primary diagnosis in 41.7% of the patients in the UC group, as compared with 27.2% of the patients in the CD group (P , 0.001). A higher number of patients had pouch failure in the CD group than the UC group, 8.5% and 4.5% respectively, P ¼ 0.03.
Characteristics of the Pouchitis Patients with IBD

Risk Factors for C. difficile Pouchitis Among IBD Inpatients
We constructed a multivariable regression model to evaluate for risk factors associated with C. difficile pouchitis. After adjustment for confounders, NAFLD (odds ratio (Tables 3 and 4) .
Secondary Outcomes
None of the patients in the study population died during their hospitalization. The percentage of patients with pouch failure or who underwent any ileostomy procedure during their hospitalization did not differ significantly between those patients with and without CDI, 5.6% versus 6%, respectively, P ¼ 0.95 (not shown in tables). In an adjusted analysis, CDI was not associated with a significantly longer average LOS or significantly higher average costs associated with hospitalization (Tables 5 and 6 ). 
DISCUSSIONS
In this large nationwide database analysis of hospitalized patients, we estimated the frequency and risk factors of CDI among patients with pouchitis. We found that the frequency of C. difficile pouchitis among patients with IBD was 2.6% as compared with 0% in pouch patients with underlying FAP. NAFLD, obesity, and OSA were found to be associated with an increased risk for C. difficile pouchitis, as our previous studies showed weight gain and visceral obesity as risk factors for chronic pouchitis. 17, 18 Clostridium difficile pouchitis seems to be a treatable condition with estimated in-hospital mortality rate of 0%.
Previous single-center studies have reported a higher frequency of CDI of 0% to 18% among patients with ileal pouch. 6, 7, 9 Our group reviewed 115 symptomatic patients with UC who underwent pouch endoscopy and found prevalence of CDI to be 18.3%. The CDI was diagnosed with enzyme immune assay. In another study of 196 symptomatic patients with ileal pouch, our group reported that 10.7% patients were tested positive for CDI with polymerase chain reaction. In contrast, a study among 48 patients with ileal pouch-anal anastomosis with enzyme immune assay from United Kingdom showed that none of the patients tested positive for CDI. A plausible explanation for this disparity of prevalence rates was due to the variability in the prevalence of symptoms and methodology among study populations. 19 The study by McLaughlin et al 10 showed that 20% of the patients had symptoms at the time of C. difficile testing. However, in the study by Shen et al and Li et al, 89% and 100% of the patients, respectively, were symptomatic at the time of C. difficile testing. We believe, in our current study, we found a lower prevalence of C. difficile pouchitis at 2.6% (99.9% CI, 1.8, 4.7) as our study population only includes hospitalized patients. As all the patients were hospitalized, we assume majority of them were symptomatic at the time of C. difficile testing and yet had a lower prevalence rate of CDI. Besides, we do not know how many patients were actually tested for C. difficile. We also believe that the higher rate of CDI in single-center studies could be influenced by referral bias. The prevalence of CDI in our current study of pouchitis inpatients with IBD is comparable with previously reported rates of CDI of 1.0% to 3.7% among IBD population in general from other large database studies that included hospitalized patients. 20, 21 Interestingly, there was no single case of CDI among FAP patients with pouchitis. Pouchitis in FAP is no more considered a rare occurrence; as reported by Quinn et al, 22 pouchitis in FAP seems to occur later than UC with a mean time to pouchitis of 4.1 years. In the current study, we do not know the proportion of patients who developed pouchitis with underlying FAP, but none of the patients with pouchitis with FAP had CDI as a secondary cause of pouchitis. Additionally, testing for CDI is assumed to be more likely in the IBD group than those in the FAP group. This alone may account for the low prevalence of CDI in FAP patients.
Our study showed NAFLD, obesity, and OSA as risk factors for CDI among pouchitis inpatients with underlying IBD. NAFLD, obesity, and OSA may be considered as a part of or being associated with metabolic syndromes. There are scant published data analyzing the association between liver diseases and CDI. Patients with liver diseases who also had CDI have been shown to have worse outcomes, especially among patients with liver cirrhosis or liver transplantation. 23, 24 Although it is unclear how NAFLD can increase the risk of CDI, recent emphasis on gut dysbiosis may provide plausible explanation linking NAFLD and CDI. Studies have suggested the role of altered intestinal microbiota or dysbiosis in the development and pathogenesis of gastrointestinal diseases, such as CDI and IBD, 25 and metabolic diseases, such as NAFLD, obesity, and type 2 diabetes mellitus. [26] [27] [28] Restoration of this altered intestinal microbiota is now seen as a means to treat people with intestinal and metabolic disorders, as evidenced by efficacy of fecal microbiota transplantation in CDI 29 and maybe IBD. 30, 31 Fecal microbiota transplantation may be beneficial for metabolic disorders. Using a mouse model, Turnbaugh et al 32 demonstrated that the transplantation of fecal microbiota from conventionally raised obese donors to lean germ-free recipients produced a greater increase in body fat content and insulin resistance than transplantation from lean donors. In a clinical trial, male white obese subjects who received intestinal microbiota from lean subjects had a significant improvement in insulin sensitivity compared with those who received autologous microbiota. 27 More recently, seen in NAFLD may explain why these patients are prone to CDI. In the multivariable analysis, obesity and OSA were other metabolic risk factors significantly associated with CDI among patients with pouchitis. It is not known how other factors besides gut dysbiosis in NAFLD, such as alterations in the innate immunity, can contribute to C. difficile pouchitis. Pouchitis represents a disease spectrum with a ranging etiologies, pathogenetic pathways, clinical presentations, and disease courses. Pouchitis is believed to be related to change in quality and/or quantity of microbiota in majority of patients, as most patients with acute pouchitis respond favorably to antibiotic therapy. The contribution of microbiota to pouchitis can be related to the presence of an abnormal quantity of pathogen or presence of dysbiosis of commensal bacteria. Clostridium difficile is considered as a pathogen, although the strain may be present in a small number of healthy individuals. Previous studies have not established the association between CDI and exposure to broad-spectrum antibiotics or proton pump inhibitors in patients with IBD 34 or pouchitis, 6, 7 in contrast to the findings in general population. However, various risk factors have been reported to be associated with acute or chronic pouchitis, such as primary sclerosing cholangitis, 35 arthralgia, 36,37 backwash ileitis, 38 and male gender. 6, 7 There are 2 interconnected theories that have been proposed by the senior author (B.S.), tissue ischemia/hypoxia, 39 and visceral obesity. 18 Blood perfusion to the gut influences the intestinal microbiota. 40 In fact, the theory of ischemia/abnormal fat deposition theory 11 based on several studies revealed a higher risk of chronic refractory pouchitis and CDI among male and obese individuals. It is believed that pouch itself is prone to ischemia due to various technical factors associated with its complex reconstruction surgery process that involves stretching of the mesentery, divisions of the superior mesenteric artery or ileocolic artery, and the risk of tension on the blood vessels that supplies the distal ileum, due to obesity, visceral fat deposition, or inherent short mesentery. Here, we would like to propose a unified theory: NAFLD and obesity, especially mesenteric obesity with abnormal fat metabolism and microvasculopathy, were found to be associated with tissue ischemia or tissue hypoxia, which promotes overgrowth of anaerobes, including C. difficile.
In contrast to the published literature, our study did not show association between gender and age with CDI. In a previously published study on CDI among patients with ileal pouch-anal anastomosis from Cleveland Clinic group, 80% of the CDI patients were male patients and male gender was a significant risk factor 6, 7 for CDI. However, the study did not demonstrate male gender as significantly associated with CDI. The discrepancy may be related to the referral and selection bias and setting (inpatients versus outpatients). In addition, CDI in this study may be considered as hospital acquired. The information on the known variables associated with CDI such as antibiotic use is not available in NIS. The higher number of comorbid conditions was significantly associated with increased resource utilization, later measured in terms of LOS and associated hospitalization costs. In a single-center study, Sun et al 8 reported comorbidities (P ¼ 0.037) as a risk factor for CDI of the pouch. Published data have shown that comorbid conditions have a great impact on hospital-based outcomes such as mortality, LOS, and hospital costs among patients with IBD with CDI. 16 Our study did not find significant association between CDI and comorbid conditions. Limited data have been reported on the association between CDI of the pouch and pouch failure. Skowron et al demonstrated that the preoperative diagnosis of CDI is an independent predictor of pouch failure (hazard ratio, 3.02; 95% CI, 1.23-7.44) among patients with UC who had undergone restorative proctocolectomy and ileal pouch-anal anastomosis. 41 However, the study did not mention any rates of C. difficile pouchitis. In another study at our institution, the occurrence of preoperative CDI did not predict CDI of the ileal pouch. 8 In the current study, we could not obtain information on preoperative CDI due to the nature of the data, but we found no association between pouch failure rate and C. difficile pouchitis. Besides, the mortality in C. difficile pouchitis patients in our study was 0% that could be attributable to their younger age and fewer comorbid conditions. Based on this, C. difficile pouchitis seems to be a well treatable condition with available antibiotic regimen.
Most studies examining CDI among patients with ileal pouch originate from single tertiary referral centers and are subjected to referral bias and limit the generalizability of these results. In particular, the role of enabling factors, such as male gender, comorbid conditions relative to CDI, and the health outcomes of CDI among patients with ileal pouch, have remained unexplored in large national data sets. To our knowledge, this is the first population-based study of patients with pouchitis in the United States. This study not only identified the prevalence and predictors of CDI pouchitis among hospitalized patients but also quantified burden of CDI among patients with ileal pouches.
Our study has important clinical implications. We have found that CDI seemed to be limited in pouchitis with underlying IBD and was absent among those with underlying FAP. Several studies have implicated dysbiosis in the pathophysiology of metabolic diseases, such as NAFLD, metabolic syndrome, obesity, and IBD. 42 Greenblum et al 43 demonstrated enzymelevel variations and topographical changes that were similar among fecal samples from healthy volunteers with IBD and obesity suggesting low diversity of gut microbiota. Current evidence suggests an association between NAFLD, obesity, OSA, and C. difficile pouchitis among patients with UC or CD.
There are a few limitations to the study. Being an administrative database, misclassification is possible. There are no separate codes for normal pouches. Medication use and prescription data were not available; hence, our results were not adjusted for the use of commonly reported "culprit" medications, such as antibiotics, proton pump inhibitors, or immunosuppressive medications. The NIS database does not separate patients who were initially admitted from those being readmitted. Therefore, it is difficult to assess factors associated with recurrent or refractory pouchitis from index admission pouchitis as CDI is known to be the cause for refractory pouchitis and treatment of CDI can lead to the resolution of symptoms. 4, 11 An important limitation is we do not know how many patients were actually tested for C. difficile during their hospitalization and the study assumes that all patients were tested for CDI. Additionally, NIS is an administrative database that does not have detailed laboratory data on how the C. difficile testing being done and confirmed. The data do not include C. difficile cases diagnosed and managed as outpatient setting who did not require hospitalization. Finally, it was not clear what were diagnostic criteria of pouchitis listed in NIS due to the limitation of the database. Ideally, pouchitis should be diagnosed based on the combined assessment of symptomatology and endoscopic evaluation with or without concurrent histologic assessment.
In conclusion, C. difficile-associated pouchitis is seen in patients with underlying IBD but not in those with FAP. Physicians should maintain a high level of suspicion for CDI while treating hospitalized IBD patients with pouchitis who have metabolic diseases, particularly NAFLD, obesity, and OSA.
